Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-03-17
DOI
10.3389/fphar.2021.636097
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents
- (2019) Lydia L. Benitez et al. DRUGS
- Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in allogeneic stem cell transplant recipients
- (2019) Alejandro Perez-Pitarch et al. THERAPEUTIC DRUG MONITORING
- Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism
- (2019) Josefine Schulz et al. DRUG METABOLISM REVIEWS
- A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug–Drug Interactions
- (2019) Xia Li et al. CLINICAL PHARMACOKINETICS
- Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults
- (2018) Naveen Mangal et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia
- (2018) Hirozumi Sano et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- PharmGKB summary
- (2017) Julia M. Barbarino et al. Pharmacogenetics and Genomics
- Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole
- (2016) Nicolas Hohmann et al. CLINICAL PHARMACOKINETICS
- CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects
- (2016) Li Zhu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Population Pharmacokinetic Analysis of Voriconazole from a Pharmacokinetic Study with Immunocompromised Japanese Pediatric Subjects
- (2015) Chieko Muto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling
- (2015) Vijay V. Upreti et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections
- (2015) Taotao Wang et al. PHARMACOTHERAPY
- Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch Regimens in Immunocompromised Japanese Pediatric Patients
- (2014) Masaaki Mori et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children
- (2014) Nicole R. Zane et al. CLINICAL PHARMACOKINETICS
- Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions
- (2014) Fang Wu et al. PHARMACEUTICAL RESEARCH
- Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use
- (2011) Bharat Damle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Original Michaelis Constant: Translation of the 1913 Michaelis–Menten Paper
- (2011) Kenneth A. Johnson et al. BIOCHEMISTRY
- Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study
- (2011) P. Soler-Palacin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers
- (2011) SeungHwan Lee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children
- (2010) T. J. Walsh et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Lack of Effect of Ginkgo biloba on Voriconazole Pharmacokinetics in Chinese Volunteers Identified as CYP2C19 Poor and Extensive Metabolizers
- (2009) He-Ping Lei et al. ANNALS OF PHARMACOTHERAPY
- Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
- (2009) Ina Scholz et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
- (2009) Peter G. Pappas et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3
- (2009) S. B. Yanni et al. DRUG METABOLISM AND DISPOSITION
- Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes
- (2008) S. B. Yanni et al. DRUG METABOLISM AND DISPOSITION
- The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
- (2008) Guo Wang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- CYP2C19Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
- (2008) Johanna Weiss et al. JOURNAL OF CLINICAL PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now